Evidence map›Paper›PMID 38391527›Full record

ArticleAntibiotics (Basel, Switzerland)2024

Meropenem plus Ertapenem and Ceftazidime-Avibactam plus Aztreonam for the Treatment of Ventilator Associated Pneumonia Caused by Pan-Drug Resistant

Konstantinos Mantzarlis, Efstratios Manoulakas, Kyriaki Parisi, Evaggelia Sdroulia, Nikolaos Zapaniotis, Vassiliki Tsolaki, Epaminondas Zakynthinos, Demosthenes Makris

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Antibiotics (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.2field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Konstantinos MantzarlisDepartment of Critical Care, University Hospital of Larissa, School of Medicine, University of Thessaly, 41110 Thessaly, Greece.ORCID 0000-0002-2453-5398
Efstratios ManoulakasDepartment of Critical Care, University Hospital of Larissa, School of Medicine, University of Thessaly, 41110 Thessaly, Greece.
Kyriaki ParisiDepartment of Critical Care, University Hospital of Larissa, School of Medicine, University of Thessaly, 41110 Thessaly, Greece.
Evaggelia SdrouliaDepartment of Critical Care, University Hospital of Larissa, School of Medicine, University of Thessaly, 41110 Thessaly, Greece.
Nikolaos ZapaniotisDepartment of Microbiology, University Hospital of Larissa, School of Medicine, University of Thessaly, 41110 Thessaly, Greece.
Vassiliki TsolakiDepartment of Critical Care, University Hospital of Larissa, School of Medicine, University of Thessaly, 41110 Thessaly, Greece.ORCID 0000-0003-2412-5388
Epaminondas ZakynthinosDepartment of Critical Care, University Hospital of Larissa, School of Medicine, University of Thessaly, 41110 Thessaly, Greece.
Demosthenes MakrisDepartment of Critical Care, University Hospital of Larissa, School of Medicine, University of Thessaly, 41110 Thessaly, Greece.
University of Thessaly · GR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionGram-negative bacteria (GNB) account for about 70% of infections in the intensive care unit (ICU) setting and are associated with significant morbidity and mortality. In recent years, pan-drug resistant (PDR) strains, strains that are not susceptible to any antibiotic, have been emerged and new treatment strategies are required.

resultsFifty eligible patients were recruited in the three groups. A statistically significant reduction in the Sequential Organ Failure Assessment (SOFA) score was observed in the control group on day 4 in comparison to day 0 of VAP ( MATERIALS AND

methodsThis is a retrospective analysis. This study was conducted in a mixed ICU in the University Hospital of Larissa, Thessaly, Greece during a three-year period (2020-2022). Patients suffering from ventilator associated pneumonia (VAP) due to carbapenem-resistant

conclusionsTreatment with CAZ-AVI +ATM or DCT may offer a clinical benefit in patients suffering with infections due to PDR

Indexed as

ceftazidime–avibactam + aztreonam treatmentClinical Pulmonary Infection Score (CPIS)double carbapenem therapymechanical ventilationpan-drug resistant K. pneumoniaSequential Organ Failure Assessment (SOFA) scoresurvivalventilator associated pneumonia (VAP)

Identifiers

PMID38391527
PMCPMC10886053
OpenAlexW4391404705

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.